Sylvia Henger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sylvia Henger has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrej Teren
Bielefeld University, Klinikum Bielefeld Mitte
1 shared publication - Anselm Arthur Derda
Klinik für Kardiologie und Angiologie, Medizinische Hochschule Hannover, Hannover, Deutschland
1 shared publication - Christoph Stellbrink
Bielefeld University, Klinikum Bielefeld Mitte
1 shared publication - Dennis Lawin
Department of Digital Medicine, Medical School OWL, Bielefeld University, Bielefeld, Germany
1 shared publication Holger Kirsten
University of Leipzig
1 shared publication- Holger Thiele
Department of Cardiology, Heart Center Leipzig at Leipzig University , Leipzig
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e048737
Cardiac Biomarkers to Refine Pretest Probability for Coronary Obstruction and Predict Survival After Revascularization in Chronic Coronary Syndrome
Background: The diagnostic and prognostic roles of cardiovascular biomarkers in chronic coronary syndrome remain unclear. Methods: Patients undergoing coronary angiography for suspected chronic coronary syndrome were prospectively enrolled (n=2251; median follow‐up 12.6 years). Obstructive coronary artery disease was defined as ≥50% stenosis in ≥1 major epicardial vessel. HsTnT (high‐sensitivity cardiac troponin T), NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity C‐reactive protein, interleukin‐6, and copeptin were measured. Receiver operating characteristic analysis and Cox regression with biomarker × treatment interaction testing were performed. Results: Overall, 888 patients (39.4%) had obstructive coronary artery disease. Only hsTnT showed meaningful diagnostic capacity (area under the curve 0.669; risk factor‐weighted clinical likelihood area under the curve 0.663), with incremental benefit inversely proportional to risk factor‐weighted clinical likelihood category (Δ area under the curve: very low 10.4%, low 8.0%, intermediate/high 5.0%). NT‐proBNP was the strongest mortality predictor across optimal medical therapy (hazard ratio [HR], 1.488 [95% CI, 1.288–1.720], P P =0.029), and coronary artery bypass grafting (HR, 1.220 [95% CI, 1.049–1.420], P =0.010). Interaction analysis validated a data‐derived 150 pg/mL threshold ( P =0.032): below it, mortality was comparably low regardless of revascularization (HR, 0.98 [95% CI, 0.67–1.43], P =0.910); above it, baseline risk was markedly elevated (HR, 5.75 [95% CI, 4.10–8.00], P P <0.001). Conclusions: HsTnT provides risk factor‐weighted clinical likelihood category‐specific incremental diagnostic value. NT‐proBNP is a universal prognostic marker identifying patients with distinct revascularization‐associated mortality reduction driven by differential baseline risk. Registration: URL: https://clinicaltrials.gov/study/NCT00497887 ; Unique Identifier: NCT00497887.
- 2 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (11) , e048737
Open AccessCardiac Biomarkers to Refine Pretest Probability for Coronary Obstruction and Predict Survival After Revascularization in Chronic Coronary Syndrome
Background: The diagnostic and prognostic roles of cardiovascular biomarkers in chronic coronary syndrome remain unclear. Methods: Patients undergoing coronary angiography for suspected chronic coronary syndrome were prospectively enrolled (n=2251; median follow‐up 12.6 years). Obstructive coronary artery disease was defined as ≥50% stenosis in ≥1 major epicardial vessel. HsTnT (high‐sensitivity cardiac troponin T), NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide), high‐sensitivity C‐reactive protein, interleukin‐6, and copeptin were measured. Receiver operating characteristic analysis and Cox regression with biomarker × treatment interaction testing were performed. Results: Overall, 888 patients (39.4%) had obstructive coronary artery disease. Only hsTnT showed meaningful diagnostic capacity (area under the curve 0.669; risk factor‐weighted clinical likelihood area under the curve 0.663), with incremental benefit inversely proportional to risk factor‐weighted clinical likelihood category (Δ area under the curve: very low 10.4%, low 8.0%, intermediate/high 5.0%). NT‐proBNP was the strongest mortality predictor across optimal medical therapy (hazard ratio [HR], 1.488 [95% CI, 1.288–1.720], P P =0.029), and coronary artery bypass grafting (HR, 1.220 [95% CI, 1.049–1.420], P =0.010). Interaction analysis validated a data‐derived 150 pg/mL threshold ( P =0.032): below it, mortality was comparably low regardless of revascularization (HR, 0.98 [95% CI, 0.67–1.43], P =0.910); above it, baseline risk was markedly elevated (HR, 5.75 [95% CI, 4.10–8.00], P P <0.001). Conclusions: HsTnT provides risk factor‐weighted clinical likelihood category‐specific incremental diagnostic value. NT‐proBNP is a universal prognostic marker identifying patients with distinct revascularization‐associated mortality reduction driven by differential baseline risk. Registration: URL: https://clinicaltrials.gov/study/NCT00497887 ; Unique Identifier: NCT00497887.